Principle of extraction:
The kit is a qualitative in vitro nucleic acid amplification assay to detect and differentiate SARS-CoV-2, influenza A virus (IFV A), and influenza B virus (IFV B) in oropharyngeal swab specimen from individuals suspected of respiratory viral infection consistent with COVID-19, suspicious clustering cases and those under investigation. This test uses a similar lab setting and procedure when compared to our SARS-CoV-2 detection assay.
Advantages:
★ Highly sensitive – Superior limit of detection
★ Highly specific – No cross-reactivity with human genome and 50 human respiratory pathogens
★ High-scalability – Ramp up testing capacity with 96-well plates
★ Easy to use – All-inclusive with pre-mixed reagents
List of product composition:
|
Component
|
Description
|
Volume 48pcs/box
|
|
SARS-CoV-2 Reagent
solution
|
Reagents for amplication,probes,
primers for virus
target and internal reference
|
240μL/pc
|
|
SARS-CoV-2 Primer and probe Mix
|
Taq polymerase,reverse transcriptase and uracil-DNA glycosylase(UDG)
|
240μL/pc
|
|
SARS-CoV-2 positive
control
|
Mix solution of pseudo-virus with target virus genes and internal reference
|
240μL/pc
|
|
SARS-CoV-2 No
template control
|
DNase/RNase free water
|
240μL/pc
|
Specifications:
|
Model
|
Product name
|
Packing size
|
Storage
|
Shelf life
|
|
IVD0058
|
SARS-CoV-2
Real-time
RT-PCR
Diagnostic Panel
|
48pcs/box
|
-20±5℃
Avoid light transport
at -15℃
|
12 months
|